A carregar...
Piecing the puzzle together: Docetaxel cycles and current considerations in the treatment of metastatic castration-resistant prostate cancer
Docetaxel is the current first line therapy for metastatic castration-resistant prostate cancer (mCRPC), but there is no standard number of docetaxel cycles given to patients. In their post hoc analysis of the Mainsail study, de Morrée et al. show that the number of docetaxel cycles administered to...
Na minha lista:
| Publicado no: | Cancer Biol Ther |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5450733/ https://ncbi.nlm.nih.gov/pubmed/28278075 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2017.1295192 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|